Palo Alto Foundation Sleep Disorders Center, Palo Alto, CA, USA.
Curr Pharm Des. 2011;17(15):1418-25. doi: 10.2174/138161211796197106.
Obstructive sleep apnea (OSA) is a growing public health hazard fueled by the obesity epidemic and an aging population. Untreated sleep apnea can result in significant consequences both in the short-term and long-term. We need to educate the public to recognize the symptoms of sleep apnea and to publicize that effective treatments are available. Positive airway pressure therapy remains the gold standard currently in treating OSA. Alternative treatments include an oral appliance or surgical options. This paper discusses the pharmacologic treatment of sleep apnea: goals include medications to address the ventilatory control of breathing, treat co-morbid diseases, treat associated health problems/complaints, address special issues, such as anesthetic precautions, and propose future targets.
阻塞性睡眠呼吸暂停(OSA)是肥胖症流行和人口老龄化带来的日益严重的公共卫生危害。未经治疗的睡眠呼吸暂停会在短期和长期内导致严重后果。我们需要教育公众认识到睡眠呼吸暂停的症状,并宣传有效的治疗方法是可用的。正压通气治疗仍然是目前治疗 OSA 的金标准。替代治疗包括口腔器械或手术选择。本文讨论了睡眠呼吸暂停的药物治疗:目标包括药物治疗来解决呼吸的通气控制,治疗合并疾病,治疗相关健康问题/投诉,解决特殊问题,如麻醉预防措施,并提出未来的目标。